According to Zacks, “Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. “
Separately, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Translate Bio in a report on Tuesday, April 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.75.
Translate Bio (NASDAQ:TBIO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.04). The business had revenue of $1.47 million during the quarter. Sell-side analysts anticipate that Translate Bio will post -1.57 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aevitas Wealth Management Inc. purchased a new position in Translate Bio in the 1st quarter worth approximately $58,000. BNP Paribas Arbitrage SA acquired a new position in shares of Translate Bio in the 1st quarter valued at approximately $63,000. Barclays PLC raised its position in shares of Translate Bio by 82.8% in the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock valued at $50,000 after purchasing an additional 3,039 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Translate Bio by 186.4% in the 1st quarter. JPMorgan Chase & Co. now owns 7,175 shares of the company’s stock valued at $73,000 after purchasing an additional 4,670 shares in the last quarter. Finally, Citigroup Inc. raised its position in shares of Translate Bio by 413.4% in the 1st quarter. Citigroup Inc. now owns 8,568 shares of the company’s stock valued at $87,000 after purchasing an additional 6,899 shares in the last quarter. Hedge funds and other institutional investors own 59.33% of the company’s stock.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Further Reading: P/E Growth (PEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.